Fate Therapeutics, Inc. (FATE)
1.85
-0.24
(-11.48%)
USD |
NASDAQ |
Nov 05, 16:00
1.81
-0.04
(-2.16%)
After-Hours: 20:00
Fate Therapeutics SG&A Expense (TTM) : 39.73M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 39.73M |
| March 31, 2026 | 42.34M |
| December 31, 2025 | 46.52M |
| September 30, 2025 | 51.12M |
| June 30, 2025 | 61.28M |
| March 31, 2025 | 67.09M |
| December 31, 2024 | 74.17M |
| September 30, 2024 | 76.84M |
| June 30, 2024 | 74.99M |
| March 31, 2024 | 80.36M |
| December 31, 2023 | 81.45M |
| September 30, 2023 | 85.10M |
| June 30, 2023 | 87.70M |
| March 31, 2023 | 85.43M |
| December 31, 2022 | 84.23M |
| September 30, 2022 | 79.58M |
| June 30, 2022 | 73.75M |
| March 31, 2022 | 65.56M |
| December 31, 2021 | 57.32M |
| September 30, 2021 | 50.70M |
| June 30, 2021 | 43.33M |
| March 31, 2021 | 38.67M |
| December 31, 2020 | 33.90M |
| September 30, 2020 | 30.25M |
| June 30, 2020 | 28.25M |
| Date | Value |
|---|---|
| March 31, 2020 | 26.02M |
| December 31, 2019 | 23.64M |
| September 30, 2019 | 21.27M |
| June 30, 2019 | 19.01M |
| March 31, 2019 | 17.55M |
| December 31, 2018 | 15.81M |
| September 30, 2018 | 14.88M |
| June 30, 2018 | 13.59M |
| March 31, 2018 | 12.44M |
| December 31, 2017 | 11.87M |
| September 30, 2017 | 10.94M |
| June 30, 2017 | 10.76M |
| March 31, 2017 | 10.34M |
| December 31, 2016 | 9.913M |
| September 30, 2016 | 10.02M |
| June 30, 2016 | 9.757M |
| March 31, 2016 | 10.20M |
| December 31, 2015 | 10.35M |
| September 30, 2015 | 9.875M |
| June 30, 2015 | 9.428M |
| March 31, 2015 | 8.81M |
| December 31, 2014 | 8.469M |
| September 30, 2014 | 8.262M |
| June 30, 2014 | 8.337M |
| March 31, 2014 | 7.757M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| AVITA Medical, Inc. | 81.89M |
| Agenus, Inc. | 38.48M |
| Amgen, Inc. | 5.299B |
| Anika Therapeutics, Inc. | 52.67M |
| BioCryst Pharmaceuticals, Inc. | 245.09M |